On Thursday, bluebird bio Inc (NASDAQ:BLUE)’s shares declined -21.95% to $70.36.
BLUE is currently valued at $3.27 billion. The company has 36.26 million shares outstanding and 98.10% shares of the company were owned by institutional investors. The company has 106.30 value in price to sale ratio while price to book ratio was recorded as 2.52. The company exchanged hands with 8.25 million shares as compared to its average daily volume of 1.60 million shares.
The mean estimate for the short term price target for bluebird bio Inc(NASDAQ:BLUE) stands at $189.00 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $241.00 while the lower price target estimate is at $108.00.
Analysts mean recommendation for the stock is 1.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer.
EXACT Sciences Corporation (NASDAQ:EXAS)’s shares gained 2.77% to $10.00.
EXAS has beta value of 0.49. The company has the market capitalization of $937.37 million. Return on assets ratio of the company was -51.70% while its return on equity ratio was -56.50%. ATR value of company was 1.20 while stock volatility for week was 13.28% while for month was 12.69%. Debt to equity ratio of the company was 0.03 and its current ratio was 11.90.
The mean estimate for the short term price target for EXACT Sciences Corporation (NASDAQ:EXAS) stands at $13.60 according to 10 Analysts. The higher price target estimate for the stock has been calculated at $22.00 while the lower price target estimate is at $7.00.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
At the end of Thursday’s trade, Acadia Healthcare Company Inc (NASDAQ:ACHC)‘s shares surged 5.11% to $72.64.
ACHC offered 56.50% EPS for prior five years. The company has 8.20% return on equity value while its ROI ratio was 5.90%. The company has $4.95 billion market capitalizations and the institutional ownership was 80.00%. Its price to book ratio was 2.98. Volatility of the stock was 5.00% for the week while for the month booked as 4.75%.
The mean estimate for the short term price target for Acadia Healthcare Company Inc(NASDAQ:ACHC) stands at $92.13 according to 15 Analysts. The higher price target estimate for the stock has been calculated at $100.00 while the lower price target estimate is at $15.
Analysts mean recommendation for the stock is 1.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
